Abeona Therapeutics Inc. (ABEO)
Abeona Therapeutics Inc. (ABEO) Stock Price, Analysis & Data
| Bid | 5.39 |
| Market Cap | 425.18M |
| Revenue (ttm) | 14.54M |
| Net Income (ttm) | 66.14M |
| Beta | 1.34 |
| EPS (ttm) | 0.96 |
| PE Ratio (ttm) | 7.77 |
| Forward PE | 26.02 |
| P/B (ttm) | 2.93 |
| P/S (ttm) | 29.18 |
| Earnings Date | Aug 13, 2026 |
| Ask | 9.36 |
| Volume | 2,203,497 |
| Avg. Volume (20D) | 1,242,688 |
| Open | 7.40 |
| Previous Close | 7.40 |
| Day's Range | 7.31 - 7.54 |
| 52-Week Range | 4.00 - 7.65 |
| Analyst | Strong Buy |
| Price Target | 20 (168.10%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ABEO
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominan...
Financial Performance
In 2025, Abeona Therapeutics's revenue was 5.82M, an increase of undefined% compared to the previous year's 0. Earnings were 71.18M, a decrease of -211.69%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for ABEO stock is "Strong Buy". The 12-month stock price forecast is 20, which is upside of 168.1% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
